Novo Nordisk announced the results from a Phase IIIb trial comparing Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
ImmunoGen Inc.’s experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving the U.S. drug developer’s shares more than 40 percent lower.
Novavax Inc.’s vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late-stage study.
A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.
AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.
A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.
Shares of Opiant Pharmaceuticals fell in trading after the company announced that the Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.
Combining 30 minutes of morning exercise with short walking breaks throughout the day may help control blood pressure.
Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.